NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00822393,Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC),https://clinicaltrials.gov/study/NCT00822393,,COMPLETED,This randomized allogeneic transplantation protocol compares i.v. Treosulfan-based conditioning therapy with reduced intensity i.v. Busulfan-based conditioning in adult AML and MDS patients at increased risk for standard conditioning therapies. The protocol is based on results of previous phase I/II trials evaluating Treosulfan/Fludarabine conditioning prior to allogeneic haematopoietic stem cell transplantation. The reference arm (reduced intensity i.v. Busulfan/Fludarabine) is considered to be accepted medical practice for the study patient population.,NO,Acute Myeloid Leukemia|Myelodysplastic Syndrome,DRUG: Busulfan|DRUG: Treosulfan,"Event-free survival (EFS), within 2 years after transplantation","Comparative evaluation of incidence of CTC grade III/IV mucositis/stomatitis between day -6 and day +28, between day -6 and day +28",,medac GmbH,,ALL,"ADULT, OLDER_ADULT",PHASE3,570,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,MC-FludT.14/L|EudraCT-No.: 2008-002356-18,2008-11-24,2018-01-25,2018-01-25,2009-01-14,,2020-07-30,"Helsinki University Central Hospital, Dept. of Medicine, Helsinki, 00290, Finland|Centre Hospitalier Lyon Sud, Lyon, 69495, France|Hopital Saint-Louis, Paris, 75475, France|Universitätsklinikum Carl Gustav Carus Dresden, Med. Klinik I, Dresden, 01307, Germany|Klinik für Knochenmarktransplantation, Essen, 45122, Germany|Malteser Krankenhaus St. Franziskus-Hospital, Flensburg, 24939, Germany|Universitätsklinikum Freiburg, Freiburg, 79106, Germany|Universitätsmedizin Goettingen, Haematolgie und Onkologie, Göttingen, 37075, Germany|Asklepios Kliniken Hamburg GmbH, Hamburg, 20099, Germany|Universitätsklinikum Heidelberg, Heidelberg, 69120, Germany|Friedrich-Schiller-Universität Jena, Jena, 07747, Germany|Universitätsklinikum Koeln, Stammzelltransplantation, Koeln, 50937, Germany|Universitätsklinikum Leipzig, Haematologie, internistische Onkologie, Leipzig, 04109, Germany|Johannes-Gutenberg-Universität Mainz, III. Medizinische Klinik, Mainz, 55131, Germany|Klinikum Rechts der Isar der TU München, III. Med. Klinik, Muenchen, 81675, Germany|Universitätsklinikum Münster, Münster, 48129, Germany|Klinikum Nürnberg, 5. Medizinische Klinik, Nürnberg, 90419, Germany|Klinikum Oldenburg gGmbH, Oldenburg, 26133, Germany|Klinikum der Universität Regensburg, Regensburg, 93053, Germany|Universität Rostock, Rostock, 18057, Germany|Universität Tübingen, Tübingen, 72076, Germany|Stiftung Deutsche Klinik für Diagnostik, Wiesbaden, 65191, Germany|Klinikum der Universität Würzburg, Würzburg, 97070, Germany|St. Istvan and St. Laszlo Hospital of Budapest, Budapest, 1097, Hungary|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, 24127, Italy|Hematology University of Brescia, Brescia, 1-25123, Italy|Scientific Institute H. San Raffaele, Milan, 20132, Italy|Ospedale Civile Pescara, Pescara, 65123, Italy|Policlinico Umberto I Univ. La Sapienza, Rome, 00161, Italy|Clinica Ematologica ed Unita di Terapie Cellulari 'Carlo Melzi', Udine, 33100, Italy|Policlinico GB Rossi (Borgo Roma), Div. di Ematologia, Verona, 37134, Italy|Medical University of Gdansk, Gdansk, 80-952, Poland|Silesian Medical University, Katowice, 40-032, Poland",
